Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002572 · ClinicalTrials.gov registry record · Phase 1
Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors
A Phase 1 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00002572 is a Phase 1 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 10 participants.
The verdict
NCT00002572, a Phase 1 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapy uses different ways to stimulate the immune system and stop cancer cells from growing. Cytotoxic T cells combined with interleukin-2 may be an effective treatment for recurrent brain tumors. PURPOSE: Phase I trial to study the effectiveness of cytotoxic T cells and interleukin-2 in treating adults with recurrent brain tumors.
Interventions
- PROCEDURE conventional surgery
- BIOLOGICAL aldesleukin
- BIOLOGICAL therapeutic tumor infiltrating lymphocytes
- BIOLOGICAL muromonab-CD3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 1994-11 |
| Est. Completion | 1999-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002572
The ClinicalTrials.gov registry entry for NCT00002572 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which conventional surgery is the first listed.
NCT00002572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002572 about?
NCT00002572 is a clinical study titled "Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors". RATIONALE: Biological therapy uses different ways to stimulate the immune system and stop cancer cells from growing. Cytotoxic T cells combined with interleukin-2 may be an effective treatment for recurrent brain tumors. PURPOSE: Phase I trial to study the effectiveness of cytotoxic T cells and int...
What is the current status of trial NCT00002572?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 1994-11. Estimated completion is 1999-12.
What interventions are being tested in trial NCT00002572?
The interventions under investigation include: conventional surgery (PROCEDURE), aldesleukin (BIOLOGICAL), therapeutic tumor infiltrating lymphocytes (BIOLOGICAL), muromonab-CD3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002572?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.